Exjade (deferasirox) binds to iron and removes it from the blood stream.

Exjade is employed to treat iron-storage disease caused by blood transfusions in adults and kids a minimum of twoyears previous.

Exjade is additionally wont to treat chronic iron-storage disease syndrome caused by a genetic blood disease in adults and kids WHO square measure a minimum of ten years previous.

Submit your review

Create your own review

Average rating:  
 0 reviews
  • Exjade, Jadenu
  • Get emergency medical help if you have any of these signs of an allergic reaction to Exjade: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

    Stop using Exjade and call your doctor at once if you have:

    problems with vision or hearing;
    kidney problems - urinating more or less than usual; painful or difficult urination; swelling in your feet or ankles; weakness, bone pain; feeling tired or short of breath;
    liver problems - nausea, upper stomach pain, itching, tired feeling, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes);
    signs of stomach bleeding - bloody or tarry stools, coughing up blood or vomit that looks like coffee grounds;
    low blood cell counts - fever, chills, flu-like symptoms, swollen gums, mouth sores, skin sores, rapid heart rate, pale skin, easy bruising, unusual bleeding, feeling light-headed; or
    severe skin reaction - fever, sore throat, swelling in your face or tongue, burning in your eyes, skin pain followed by a red or purple skin rash that spreads (especially in the face or upper body) and causes blistering and peeling.
    Serious side effects may be more likely in older adults.

    Common Exjade side effects may include:

    nausea, vomiting, stomach pain;
    diarrhea; or
    skin rash.
  • Exjade therapy should only be considered when a patient has evidence of chronic transfusional iron overload. The evidence should include the transfusion of at least 100 mL/kg of packed red blood cells (e.g., at least 20 units of packed red blood cells for a 40 kg person or more in individuals weighing more than 40 kg), and a serum ferritin consistently greater than 1000 mcg/L. Prior to starting therapy, obtain: • serum ferritin level • baseline serum creatinine in duplicate (due to variations in measurements) and determine the creatinine clearance (Cockcroft-Gault method) • serum transaminases and bilirubin • baseline auditory and ophthalmic examinations • The recommended initial dose of Exjade for patients 2 years of age and older is 20 mg per kg body weight orally, once daily. Calculate doses (mg per kg per day) to the nearest whole tablet. After commencing therapy, monitor serum ferritin monthly and adjust the dose of Exjade, if necessary, every 3-6 months based on serum ferritin trends. Make dose adjustments in steps of 5 or 10 mg per kg and tailor adjustments to the individual patient’s response and therapeutic goals. In patients not adequately controlled with doses of 30 mg per kg (e.g., serum ferritin levels persistently above 2500 mcg/L and not showing a decreasing trend over time), doses of up to 40 mg per kg may be considered. Doses above 40 mg per kg are not recommended. If the serum ferritin falls consistently below 500 mcg/L, consider temporarily interrupting therapy with Exjade